Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 46
Filtrar
1.
Ir Med J ; 112(10): 1016, 2019 12 16.
Artigo em Inglês | MEDLINE | ID: mdl-32311243

RESUMO

Aim This study aims to investigate the disease frequency of Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) among the Irish population. Methods Children (<18 years) with MCADD were identified via the National Centre for Inherited Metabolic Disorders and the metabolic laboratory at Temple Street Children's University Hospital. Central Statistics Office population data was used to calculate epidemiological figures. Results From 1998 to 2016, 17 children (<18 years) were diagnosed with MCADD including two patients whose initial presentation was fatal. The mean age at initial presentation was 1.48 years (Range: 0.005 to 2.86). The incidence was 1:71650 with mortality at 15.38%. No child subsequently died post diagnosis. The common c.985A>G mutation accounted for 88% of alleles. Conclusion The incidence of MCADD in Ireland is lower than global estimates. The potential for under-ascertainment and late diagnosis of cases exists in Ireland and is of concern for a treatable condition with a significant mortality when undiagnosed. The authors welcome the introduction of MCADD to the National Newborn Bloodspot Screening Program.


Assuntos
Acil-CoA Desidrogenase/deficiência , Erros Inatos do Metabolismo Lipídico/diagnóstico , Erros Inatos do Metabolismo Lipídico/epidemiologia , Adolescente , Criança , Pré-Escolar , Feminino , Testes Genéticos/métodos , Humanos , Incidência , Lactente , Recém-Nascido , Irlanda , Masculino , Triagem Neonatal/métodos
2.
Ir J Med Sci ; 185(1): 241-8, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25894277

RESUMO

BACKGROUND: Investigation of patients, particularly children, with unexplained global developmental delay (GDD)/learning disability (LD) has been challenging due to a lack of clear guidance from specialised centres. Limited knowledge of rare diseases and a poor understanding of the purpose or limitations of appropriate investigations have been some of the principal reasons for this difficulty. AIMS: A guideline development group was formed to recommend on appropriate, first line metabolic, genetic and radiological investigations for children and adults with unexplained GDD/ID. METHODS AND RECOMMENDATIONS: A comprehensive literature search was conducted, evaluated and reviewed by the guideline committee and a best practice protocol for first line assessment and genetic, metabolic and radiological investigations was decided upon after considering diagnostic yield, practicality, treatability and costs. CONCLUSION: It is hoped that these recommendations will become national guidelines for the first line metabolic, genetic and radiological investigation of patients presenting with unexplained GDD/ID.


Assuntos
Deficiências do Desenvolvimento/diagnóstico , Deficiências da Aprendizagem/diagnóstico , Erros Inatos do Metabolismo/diagnóstico , Adulto , Criança , Deficiências do Desenvolvimento/genética , Deficiências do Desenvolvimento/metabolismo , Humanos , Deficiências da Aprendizagem/genética , Deficiências da Aprendizagem/metabolismo , Erros Inatos do Metabolismo/genética , Erros Inatos do Metabolismo/metabolismo , Doenças Raras
3.
Ir Med J ; 108(10): 312-4, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26817292

RESUMO

DHPR deficiency is a rare autosomal recessively inherited metabolic disorder of tetrahydrobiopterin (BH4) regeneration. Clinical symptoms may comprise microcephaly, developmental delay, ataxia and seizures. BH4 is the cofactor for the enzyme phenylalanine (Phe)hydroxylase (PAH), and for tryptophan and tyrosine hydroxylases, both of which are essential for serotonin and dopamine biosynthesis. We present four patients in two families who are being treated at the National Centre for Inherited Metabolic Disorders (NCIMD). All are members of the Irish Traveller population. We have identified a homozygous mutation, c.353C>T, in the DHPR (QDPR) gene which, to the best of our knowledge, has not been previously described. The mainstay of treatment is a life-long Phe-restricted diet together with supplementation of L-dopa and 5-hydroxy tryptophan (5-HT) and folinic acid. In Ireland, there is neurological comorbidity in our adult DHPR patients, although the overall outcome is satisfactory and one affected female has three healthy children.


Assuntos
Di-Hidropteridina Redutase/genética , Fenilcetonúrias/genética , Adulto , Feminino , Humanos , Lactente , Masculino
4.
J Inherit Metab Dis ; 36(1): 21-7, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22870861

RESUMO

Newborn screening for the inborn error of metabolism, classical galactosaemia prevents life-threatening complications in the neonatal period. It does not however influence the development of long-term complications and the complex pathophysiology of this rare disease remains poorly understood. The objective of this study was to report the development of a healthcare database (using Distiller Version 2.1) to review the epidemiology of classical galactosaemia in Ireland since initiation of newborn screening in 1972 and the long-term clinical outcomes of all patients attending the National Centre for Inherited Metabolic Disorders (NCIMD). Since 1982, the average live birth incidence rate of classical galactosaemia in the total Irish population was approximately 1:16,476 births. This reflects a high incidence in the Irish 'Traveller' population, with an estimated birth incidence of 1:33,917 in the non-Traveller Irish population. Despite early initiation of treatment (dietary galactose restriction), the long-term outcomes of classical galactosaemia in the Irish patient population are poor; 30.6 % of patients ≥ 6 yrs have IQs <70, 49.6 % of patients ≥ 2.5 yrs have speech or language impairments and 91.2 % of females ≥ 13 yrs suffer from hypergonadotrophic hypogonadism (HH) possibly leading to decreased fertility. These findings are consistent with the international experience. This emphasizes the requirement for continued clinical research in this complex disorder.


Assuntos
Galactosemias/complicações , Galactosemias/epidemiologia , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Galactosemias/diagnóstico , Galactosemias/tratamento farmacológico , Humanos , Incidência , Lactente , Recém-Nascido , Irlanda/epidemiologia , Masculino , Pessoa de Meia-Idade , Triagem Neonatal/métodos , Estudos Retrospectivos , Tempo , Resultado do Tratamento , Adulto Jovem
5.
Ir J Med Sci ; 180(4): 807-11, 2011 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-21660651

RESUMO

BACKGROUND: The overall seroprevalence of toxoplasma antibodies in women of childbearing age in Ireland is 25% [1]. Hence, 75% of women remain susceptible to primary toxoplasma infection during pregnancy, which if transmitted to the foetus can cause ocular, neurological and other sequelae. Toxoplasma exposure during pregnancy can be avoided if there is an awareness of the potential sources of infection, mainly contaminated food, water, soil and cat faeces. AIMS: To determine risk factor exposure in a cohort of women with congenitally infected infants and to assess maternal risk awareness prior to diagnosis of infection. METHODS: Data, prospectively gathered during 2 years of pilot newborn screening for congenital toxoplasmosis in Ireland, was retrospectively analysed. Known risk factors for acquisition of infection were identified. Women were questioned regarding risk awareness and implementation of avoidance measures, if any, during pregnancy. RESULTS: Fifteen congenitally infected infants were identified by newborn screening. Seventy-three percent of their mothers (11/15) reported lack of knowledge concerning risk factors for toxoplasma infection or its potential threat to the foetus. Ingestion of raw or undercooked meat during pregnancy was the predominant source of toxoplasma cyst exposure identified. Contact with cats was reported in just one case. CONCLUSIONS: Most women were uneducated about the risks posed by Toxoplasma gondii exposure during pregnancy. There is a clear need for better educational programmes regarding primary prevention of congenital toxoplasmosis if neonatal infection is to be avoided.


Assuntos
Conhecimentos, Atitudes e Prática em Saúde , Complicações Infecciosas na Gravidez/etiologia , Toxoplasmose Congênita/parasitologia , Toxoplasmose/etiologia , Adulto , Feminino , Humanos , Gravidez , Complicações Infecciosas na Gravidez/prevenção & controle , Estudos Retrospectivos , Fatores de Risco , Toxoplasmose/prevenção & controle , Toxoplasmose Congênita/prevenção & controle , Adulto Jovem
6.
Heredity (Edinb) ; 104(2): 148-54, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19639008

RESUMO

Classical or transferase-deficient galactosaemia is an inherited metabolic disorder caused by mutation in the human Galactose-1-phosphate uridyl transferase (GALT) gene. Of some 170 causative mutations reported, fewer than 10% are observed in more than one geographic region or ethnic group. To better understand the population history of the common GALT mutations, we have established a haplotyping system for the GALT locus incorporating eight single nucleotide polymorphisms and three short tandem repeat markers. We analysed haplotypes associated with the three most frequent GALT gene mutations, Q188R, K285N and Duarte-2 (D2), and estimated their age. Haplotype diversity, in conjunction with measures of genetic diversity and of linkage disequilibrium, indicated that Q188R and K285N are European mutations. The Q188R mutation arose in central Europe within the last 20 000 years, with its observed east-west cline of increasing relative allele frequency possibly being due to population expansion during the re-colonization of Europe by Homo sapiens in the Mesolithic age. K285N was found to be a younger mutation that originated in Eastern Europe and is probably more geographically restricted as it arose after all major European population expansions. The D2 variant was found to be an ancient mutation that originated before the expansion of Homo sapiens out of Africa.


Assuntos
Galactosemias/enzimologia , Frequência do Gene , Mutação de Sentido Incorreto , UDPglucose-Hexose-1-Fosfato Uridiltransferase/genética , Europa (Continente) , Feminino , Galactosemias/genética , Humanos , Masculino , Polimorfismo de Nucleotídeo Único , UDPglucose-Hexose-1-Fosfato Uridiltransferase/deficiência , População Branca/genética
7.
Ir Med J ; 101(7): 220-1, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18807815

RESUMO

Congenital toxoplasmosis (CT) arises as a result of new acquisition of Toxoplasma infection by a susceptible woman during pregnancy. Early detection of CT through neonatal screening programmes could optimize management and improve infant outcome. This study sought to estimate the prevalence of Toxoplasma susceptibility in pregnant women. As detection of Toxoplasma antibodies in neonatal blood reflects maternal exposure history, maternal antibody seroprevalence was determined using anonymized residual blood from newborn screening cards. A total of 20,252 cards were tested in 1 year. 4,991 (24.6%) cards tested positive for Toxoplasma antibody. Results were stratified by county. Toxoplasma antibody seroprevalence rates of 25% indicated that Toxoplasma infection is common in Ireland and that up to 75% of women remain susceptible to primary infection during pregnancy. This study aimed to a) determine the seroprevalence of Toxoplasma antibody in pregnant women, and hence b) estimate the risk for acquisition of primary toxoplasmosis in pregnancy in order to support an application to fund a pilot newborn screening programme.


Assuntos
Suscetibilidade a Doenças , Triagem Neonatal , Toxoplasmose Congênita/diagnóstico , Feminino , Humanos , Recém-Nascido , Irlanda/epidemiologia , Gravidez , Fatores de Risco , Estudos Soroepidemiológicos , Toxoplasmose Congênita/sangue , Toxoplasmose Congênita/epidemiologia
8.
J Pediatr Endocrinol Metab ; 21(2): 155-63, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18422028

RESUMO

UNLABELLED: Thyroid dysfunction is more common in individuals with Down's syndrome (DS) than in the general population, whose clinical features can mask the presenting signs and symptoms of hypothyroidism. Biochemical screening is necessary; however, venepuncture may be difficult. AIMS: To assess the prevalence of thyroid dysfunction in children and adolescents with DS and the feasibility of screening for hypothyroidism using capillary dried blood spot thyroid stimulating hormone (TSH) from infancy. METHODS: 394 children (217 boys, 177 girls) were clinically assessed for thyroid dysfunction and 305 children (aged 4 months to 18.9 years) were screened for hypothyroidism by capillary whole blood TSH sample. RESULTS: Thyroid dysfunction was detected in 4.6%, with 50% unscreened since neonatal screening. Parents reported minimal distress by fingerprick screening. CONCLUSION: DS is associated with an increased prevalence of thyroid dysfunction, particularly in preschool children. Biochemical screening is essential and capillary whole blood TSH sampling for hypothyroidism is feasible, less invasive and acceptable.


Assuntos
Síndrome de Down/complicações , Hipotireoidismo/etiologia , Tireotropina/sangue , Adolescente , Biomarcadores/sangue , Criança , Pré-Escolar , Estudos de Viabilidade , Feminino , Humanos , Hipotireoidismo/sangue , Hipotireoidismo/epidemiologia , Lactente , Masculino , Testes de Função Tireóidea
9.
Arch Dis Child Fetal Neonatal Ed ; 93(4): F257-60, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-18218660

RESUMO

BACKGROUND: B-type natriuretic peptide (BNP) is a marker for ventricular dysfunction secreted as a pre-prohormone, pro-B-type natriuretic peptide (proBNP), and cleaved into BNP and a biologically inactive fragment, N-terminal pro-B-type natriuretic peptide (NT-proBNP). Little is known about the clinical usefulness of NT-proBNP in preterm infants. OBJECTIVE: To evaluate the usefulness of plasma NT-proBNP in diagnosing haemodynamically significant patent ductus arteriosus (hsPDA) in neonates and examine some factors that might affect this. METHODS: Infants born at <34 weeks' gestational age (GA) and <2 kg birth weight (BW) were prospectively enrolled within 6-12 hours of birth. Plasma NT-proBNP levels were measured on days 1, 3, 5 and 10 with simultaneous echocardiography done to detect hsPDA and assess ventricular function. Significant PDA was diagnosed by large ductal flow with left to right shunt on colour Doppler, measuring >1.6 mm on two-dimensional echocardiography, along with clinical features of PDA. RESULTS: Forty-nine infants were analysed. Median GA was 30 weeks (range 24-33) and median BW 1220 g (range 550-1950). Eighteen infants with hsPDA had higher day 3 plasma NT-proBNP values (median 32 907 pg/ml; range 11 396-127 155) (p<0.001) than controls (median 3147 pg/ml; range 521-10 343). Infants who developed sepsis had higher day 10 plasma NT-proBNP levels. Area under receiver operator characteristic curve for detection of hsPDA, by day 3 NT-proBNP value, was significant 0.978 (95% CI 0.930 to 1.026). NT-proBNP was predictive of hsPDA (sensitivity 100%; specificity 95%) at a cut-off value of 11 395 pg/ml. CONCLUSION: Plasma NT-proBNP level on day 3 is a good marker for hsPDA in preterm infants. Serial measurements of NT-proBNP may be useful in assessing the clinical course of PDA.


Assuntos
Permeabilidade do Canal Arterial/diagnóstico , Peptídeo Natriurético Encefálico/sangue , Fragmentos de Peptídeos/sangue , Biomarcadores/sangue , Feminino , Humanos , Recém-Nascido , Recém-Nascido Prematuro , Masculino , Estudos Prospectivos , Sensibilidade e Especificidade
10.
Ir Med J ; 99(9): 262-4, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17144232

RESUMO

Mitochondrial respiratory chain disorders account for significant and varied presentations in paediatric practice. The true prevalence of these disorders in the paediatric population is still not well documented with predicted geographic variation. We report a retrospective analysis over a seven year period of cases presenting to a tertiary care centre and associated clinical features. The overall prevalence of mitochondrial disorders in our population is higher than expected (1/9,000 births), explained in part by multiple presentations in a consanguineous subgroup of the population (Irish travellers).


Assuntos
Doenças Mitocondriais/epidemiologia , Humanos , Incidência , Irlanda/epidemiologia , Doenças Mitocondriais/diagnóstico , Doenças Mitocondriais/genética , Fenótipo
11.
J Inherit Metab Dis ; 27(6): 917-20, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15505400

RESUMO

Twenty-one patients have been diagnosed with glutaric aciduria type I over a 16-year period in the Republic of Ireland, 11 following clinical presentation and 10 following a high-risk screen. Nineteen have been managed with diet. Eight patients have died, of whom 7 were diagnosed clinically. Six had dystonic and one spastic cerebral palsy. Of the 11 patients who did not have cerebral palsy, 10 were diagnosed following a high-risk screen. Seven of the 11 have no abnormal neurological signs; 6 of the 7 have abnormal CT or MRI findings; and no case of striatal degeneration has occurred during the past 14 years in the high-risk screened group.


Assuntos
Erros Inatos do Metabolismo dos Aminoácidos/terapia , Glutaratos/urina , Adolescente , Adulto , Erros Inatos do Metabolismo dos Aminoácidos/epidemiologia , Erros Inatos do Metabolismo dos Aminoácidos/mortalidade , Encefalopatias/etiologia , Encefalopatias/patologia , Criança , Pré-Escolar , Feminino , Cromatografia Gasosa-Espectrometria de Massas , Glutaril-CoA Desidrogenase , Humanos , Lactente , Irlanda/epidemiologia , Imageamento por Ressonância Magnética , Masculino , Mutação/genética , Mutação/fisiologia , Neostriado/patologia , Oxirredutases atuantes sobre Doadores de Grupo CH-CH/deficiência , Oxirredutases atuantes sobre Doadores de Grupo CH-CH/genética , Resultado do Tratamento
12.
J Inherit Metab Dis ; 24(2): 305-8, 2001 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11405350

RESUMO

This workshop was organized as a direct response to concerns and queries raised by laboratory personnel, both in Europe and in the United States, about the imminent withdrawal of Beckman Coulter from the amino acid analysis market. The topics covered included external quality control schemes, standard operating procedures for amino acid analysis and instrumentation, both from a user's perspective and that of the company representatives. There was a discussion panel of all speakers following the presentations.


Assuntos
Aminoácidos/análise , Técnicas de Laboratório Clínico/instrumentação , Controle de Qualidade
13.
Hum Mutat ; 17(5): 432, 2001 May.
Artigo em Inglês | MEDLINE | ID: mdl-11317360

RESUMO

Mutation detection methods based upon chemical or enzymatic cleavage of DNA offer excellent detection efficiencies coupled with high throughput and low unit cost. We describe the application of the novel technique of Glycosylase Mediated Polymorphism Detection (GMPD) to the detection of two of the most common mutations of the PAH gene in the Irish population that cause phenylketonuria (PKU), R408W and I65T, which occur at relative frequencies of 41.0% and 10.4% respectively. GMPD assays for R408W and I65T were developed permitting fluorescent detection of cleavage products on the ALFexpresstrade mark automated DNA sequencer. The method was validated by screening a panel of PKU patients whose mutant genotypes had previously been characterised by standard methods. It also proved possible to perform multiplex detection of the two mutations by co-electrophoresis of GMPD products. GMPD is a rapid and robust method for the detection of the R408W and I65T mutations, whose key advantage lies in its use of a pair of enzymes with high cleavage efficiency to detect a number of mutations as compared to the use of individual digestions with a range of specific restriction endonuclease enzymes. Hum Mutat 17:432, 2001.


Assuntos
DNA Glicosilases , Testes Genéticos/métodos , Mutação de Sentido Incorreto/genética , N-Glicosil Hidrolases/metabolismo , Fenilalanina Hidroxilase/genética , Fenilcetonúrias/genética , Polimorfismo Genético/genética , Alelos , Sequência de Bases , Análise Mutacional de DNA/métodos , Éxons/genética , Frequência do Gene , Genótipo , Humanos , Recém-Nascido , Irlanda , Dados de Sequência Molecular , Fenilcetonúrias/enzimologia , Reação em Cadeia da Polimerase/métodos , Reprodutibilidade dos Testes , Sensibilidade e Especificidade , Fatores de Tempo , Uracila-DNA Glicosidase
14.
Am J Med Genet ; 86(1): 71-4, 1999 Sep 03.
Artigo em Inglês | MEDLINE | ID: mdl-10440833

RESUMO

Folic acid can prevent neural tube defects; in some cases the mechanism is probably a correction of a metabolic defect caused by thermolabile methylenetetrahydrofolate reductase (MTHFR) found in increased frequency in cases. It is less clear whether folic acid can prevent oral clefts, in part because it is not known whether thermolabile MTHFR is more common in those with oral clefts. This study examined the prevalence of the mutation (677 C-->T) that causes thermolabile MTHFR in subjects with oral clefts from a national Irish support group, and an anonymous control group randomly selected from a neonatal screening program covering all births in Ireland. Eighty-three of 848 control subjects were homozygous (TT) thermolabile MTHFR (9.8%). This defect was almost three times as common in the 27 subjects (25.9%) with isolated cleft palate (odds ratio 3.23, 95% confidence interval 1.32 -7.86, P = 0. 02) and somewhat more common in the 66 subjects with cleft lip with or without cleft palate (15.2%, odds ratio 1.65, 95% confidence interval 0.81-3.35, P = 0.20). When the two groups with different etiologies were combined, the overall odds ratio was 2.06 (95% confidence interval 1.16-3.66, P = 0.02). In the Irish population homozygosity for the common folate-related polymorphism associated with thermolabile MTHFR is significantly more frequent in those with isolated cleft palate, and could be etiologically important. Am. J. Med. Genet. 86:71-74, 1999. Published 1999 Wiley-Liss, Inc.


Assuntos
Fenda Labial/enzimologia , Fissura Palatina/enzimologia , Mutação , Oxirredutases atuantes sobre Doadores de Grupo CH-NH/genética , Criança , Fenda Labial/etiologia , Fenda Labial/genética , Fissura Palatina/etiologia , Fissura Palatina/genética , Estabilidade Enzimática , Saúde da Família , Feminino , Ácido Fólico/metabolismo , Frequência do Gene , Homozigoto , Humanos , Recém-Nascido , Irlanda , Masculino , Metilenotetra-Hidrofolato Redutase (NADPH2) , Razão de Chances , Oxirredutases atuantes sobre Doadores de Grupo CH-NH/metabolismo , Polimorfismo Genético/genética , Temperatura
16.
Thromb Haemost ; 81(4): 502-5, 1999 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10235428

RESUMO

Thrombosis is the major cause of morbidity and mortality in individuals with untreated classical homocystinuria (HCU) due to cystathionine beta-synthase deficiency and characterised by severe hyperhomocysteinaemia. In addition, mild and moderate hyperhomocysteinaemia and Factor V Leiden (FVL; Arg506Gln) have recently been identified as thrombotic risk factors. FVL. which renders resistance to activated Protein C, is the most common inherited genetic risk factor for thrombosis with a high allelic frequency amongst Caucasians. As thrombophilia is a multigenic disorder, 26 individuals with HCU (median age 17.6 years, range 3.5-32.8 years) and 36 obligate heterozygotes (median age 51.5 years, range 34-74 years) were screened for FVL. All the HCU individuals received treatment, except one, within 6 weeks of birth for those who were diagnosed at birth through the national newborn screening programme (n = 20) and at the time of diagnosis for those late detected (n = 5, mean age of starting treatment 4.9 years, range 1.4-11 years). All had been free from venous thrombosis, except one HCU individual and one HCU obligate heterozygote. Neither of the two individuals with venous thrombosis carried FVL. Two independent individuals with HCU (male 14.8 years; female 18.2 years) were heterozygous for FVL (allelic frequency 3.8%) and three independent HCU obligate heterozygotes (males 40 and 45.8 years; female 45.6 years) were also heterozygous for FVL (allelic frequency 4.16%). The findings in this small group suggest that FVL is not a mandatory but a significant confounding risk factor for the occurrence of thrombosis in HCU individuals and additional contributing factors may be required for thrombosis to occur in HCU obligate heterozygotes with FVL heterozygosity. Our data also suggest that treatment of HCU not only reduces the thrombotic risk in patients with isolated HCU but also in those with the additional FVL heterozygosity.


Assuntos
Cistationina beta-Sintase/deficiência , Fator V/genética , Trombose Venosa/etiologia , Adolescente , Adulto , Idoso , Alelos , Feminino , Frequência do Gene , Heterozigoto , Homocistinúria/etiologia , Homocistinúria/genética , Homozigoto , Humanos , Hiper-Homocisteinemia/etiologia , Hiper-Homocisteinemia/genética , Masculino , Pessoa de Meia-Idade , Mutação Puntual , Fatores de Risco , Trombose Venosa/genética
17.
Eur J Pediatr ; 157 Suppl 2: S84-7, 1998 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-9587032

RESUMO

Newborn screening for cystathionine beta-synthase deficiency (homocystinuria; HCU) was started in the late 1960s using a bacterial inhibition assay (BIA). At least seven countries have either national or regional screening programmes; 12 programmes are known to have discontinued. The worldwide incidence of HCU is approximately 1 in 335,000 but varies from 1:65,000 (Ireland) to 1:900,000 (Japan). Methodologies include the BIA, one-dimensional or thin-layer amino acid chromatography and, more recently, tandem mass spectrometry. The BIA diagnostic cut off concentration of blood methionine varies from 67 to 270 micromol/ (10-40 mg/l) with a median of 135 micromol/l (20 mg/l). In Ireland, 25 cases of HCU from 19 families have been identified from 1.58 million newborn infants since 1971; 21 cases were detected through the screening programme. Of the four missed cases, three were breast-fed at the time of blood collection and one was pyridoxine responsive. These findings were in broad agreement with the results from five other programmes, in which approximately one in every five cases was missed by the screening programme. Early hospital discharge, low protein intake, high blood methionine cut-off concentration and pyridoxine responsiveness were all identified as contributing to missed cases.


Assuntos
Homocistinúria/prevenção & controle , Triagem Neonatal , Homocistinúria/sangue , Homocistinúria/epidemiologia , Humanos , Incidência , Recém-Nascido , Irlanda/epidemiologia , Metionina/sangue , Mutação , Estudos Retrospectivos
20.
Atherosclerosis ; 103(2): 171-80, 1993 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-8292093

RESUMO

Familial hypercholesterolaemia (FH) is caused by mutations in the gene for the low density lipoprotein (LDL) receptor. It is generally believed that homozygous FH patients do not respond well to lipid-lowering drug therapy with inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase because they cannot respond to an increased demand for hepatic cholesterol by up-regulation of LDL-receptor activity. In this paper we show that serum cholesterol in a homozygous FH patient with a receptor-negative LDL-receptor phenotype was reduced by 30% after treatment with simvastatin alone and by a further 11% with simvastatin in combination with probucol and nicotinic acid. The patient was a true homozygote, with two identical alleles of the LDL receptor gene in which a previously undescribed point mutation in exon 11 introduces a premature termination codon at residue 540 in the protein; the mutant protein is predicted to be truncated in the domain with homology to the epidermal growth factor precursor. Cultured cells from the patient were unable to bind, internalise or degrade LDL by the receptor pathway and there was no immunodetectable LDL receptor protein in the cells. Thus the lipid lowering effect of simvastatin in this individual must involve mechanisms other than stimulation of LDL receptors.


Assuntos
Anticolesterolemiantes/uso terapêutico , Colesterol/sangue , Homozigoto , Hiperlipoproteinemia Tipo II/tratamento farmacológico , Receptores de LDL/genética , Adolescente , Adulto , Criança , Feminino , Humanos , Hiperlipoproteinemia Tipo II/sangue , Hiperlipoproteinemia Tipo II/genética , Lovastatina/análogos & derivados , Lovastatina/uso terapêutico , Masculino , Pessoa de Meia-Idade , Niacina/uso terapêutico , Linhagem , Polimorfismo Genético , Probucol/uso terapêutico , Sinvastatina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...